Entest (PK) Stock Price

0.00 (0.0%)
Best deals to access real time data!
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Canna Trader Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Entest Group Inc (PK) ETNI OTCMarkets Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
0.00 0.0% 0.0038 0.00 0.00 0.00 0.0038 20:00:00
Bid Price Ask Price Spread Spread % News
0.0011 0.005 0.0039 78.0% - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.0038 USD

Entest (PK) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 186.85k 49.17M 17.04M $ - $ - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
1.98k $ - 0.00% - -

more financials information »

Entest (PK) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ETNI Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.00380.00380.00380.00383,3340.000.0%
1 Month0.005040.005040.00360.00389128,749-0.00124-24.6%
3 Months0.00550.0080.00350.00516335,993-0.0017-30.91%
6 Months0.0090.01040.00350.006120350,067-0.0052-57.78%
1 Year0.01580.0230.00350.009018941,885-0.012-75.95%
3 Years0.0334580.08890.00350.024423842,994-0.02966-88.64%
5 Years0.00020.09190.00010.0073402253,5940.00361,800.0%

Entest (PK) Description

Entest BioMedical, Inc. is a biotechnology company dedicated to developing treatments that harness the body's own reparative/immunological mechanisms. The Company is currently developing Immuno-Therapeutic Cancer Vaccines for dogs. The Company sees applications for its areas of focus in beyond animal venues to human applications. The Company has adopted a veterinary first approach, believing once efficacy in animals is established and near term revenue achieved, viability in transitioning to human applications can be made via joint ventures and license agreements.

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.